San Diego-based Ocera Therapeutics has raised $12 million in a second round of financing. New investor Sofinna Ventures led the round, with contributions from Domain Associates and Thomas, McNerney & Partners. The funding will go toward development of AST-120, a treatment for Crohn's disease. The company initiated Phase III clinical trial for the treatment in the first quarter of this year.
- take a look at Ocera's press release